Neurocrine Biosciences (NBIX) Receivables - Net (2010 - 2026)

Neurocrine Biosciences' Receivables - Net history runs 17 years deep, the most recent figure standing at $768.1 million for Q1 2026.

• Quarterly Receivables - Net rose 48.86% year-over-year to $768.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $768.1 million (up 48.86% YoY) and the FY2025 annual result came in at $686.8 million, up 43.35% from the prior year.
• Receivables - Net was $768.1 million for Q1 2026 at Neurocrine Biosciences, up from $686.8 million in the prior quarter.
• Across five years, Receivables - Net topped out at $768.1 million in Q1 2026 and bottomed at $263.5 million in Q1 2022.
• A 5-year average of $470.8 million and a median of $450.7 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2022 — Receivables - Net jumped 88.68% — and 2024, when it gained 9.06%.
• Neurocrine Biosciences' Receivables - Net stood at $350.0 million in 2022, then rose by 25.51% to $439.3 million in 2023, then gained by 9.06% to $479.1 million in 2024, then soared by 43.35% to $686.8 million in 2025, then grew by 11.84% to $768.1 million in 2026.
• Business Quant data shows NBIX's Receivables - Net at $768.1 million in Q1 2026, $686.8 million in Q4 2025, and $728.0 million in Q3 2025.